Three Horizons Framework
for Manufacture of irradiation, electromedical and electrotherapeutic equipment (ISIC 2660)
This industry thrives on innovation but is burdened by immense R&D costs (IN05), long development cycles, and regulatory complexity (IN04). The framework provides a structured way to manage short-term profitability, mid-term growth, and long-term disruptive innovation, which is vital given the risk...
Strategic Overview
The Three Horizons Framework is critically important for manufacturers of irradiation, electromedical, and electrotherapeutic equipment, an industry characterized by high R&D intensity (IN05), long development cycles, and continuous technological advancement coupled with significant regulatory hurdles (IN04, SC05). This framework enables companies to strategically balance investments across current profitable products (Horizon 1), emerging growth opportunities (Horizon 2), and disruptive future technologies (Horizon 3). This structured approach is essential for managing portfolio risks, optimizing resource allocation, and sustaining long-term competitiveness in a rapidly evolving market with high obsolescence risks (MD01).
By systematically categorizing and managing innovation efforts, the framework helps mitigate the challenges of high R&D burden (IN05), talent scarcity (ER07), and the need for continuous technological adaptation (IN02). It provides a clear roadmap for allocating budgets and talent, fostering strategic partnerships, and navigating complex regulatory pathways across different timeframes. This ensures that today's profits are used to fuel tomorrow's breakthroughs, preventing market stagnation and enabling the company to shape future healthcare paradigms rather than merely reacting to them.
5 strategic insights for this industry
Balancing H1 Profitability with H2/H3 Innovation Funding
The framework enables strategic allocation of capital, ensuring that the profitability of existing, mature electromedical devices (H1) directly funds the R&D for next-generation platforms (H2) and speculative, potentially disruptive technologies (H3). This is crucial given the high capital expenditure for R&D (IN05) and the need to manage revenue volatility from product cycles (MD01).
Strategic R&D Portfolio Management and Risk Mitigation
It provides a clear structure for managing a diverse R&D portfolio, segmenting projects by their risk, reward, and time horizon. This helps in prioritizing R&D efforts (IN03), avoiding misallocation of resources (IN01), and mitigating the high-risk nature of developing breakthrough medical technologies (IN05).
Navigating Complex and Evolving Regulatory Pathways
Each horizon demands distinct regulatory strategies: H1 focuses on maintaining compliance for existing devices, H2 on securing new market approvals (e.g., FDA, CE mark) for novel products, and H3 on influencing future regulatory frameworks for entirely new therapeutic modalities. This directly addresses the challenge of navigating complex regulatory pathways (IN04).
Addressing Talent Gaps and Technology Adoption
The framework helps identify specific talent needs for each horizon: H1 requires skilled engineers for product enhancements; H2 needs AI/ML specialists, data scientists, and advanced material engineers; H3 demands experts in emerging fields like quantum computing, synthetic biology, or advanced robotics. This aids in managing talent scarcity and adapting to new technologies (IN02, ER07).
Guiding Strategic Partnerships and M&A Activities
The framework informs partnership and acquisition strategies: H1 might focus on distribution or service partners; H2 could involve collaborations with AI startups or specialized component providers; H3 may target academic spin-offs or early-stage ventures exploring truly disruptive science, aligning with the goal of growth and future market creation.
Prioritized actions for this industry
Establish distinct organizational units or dedicated teams with separate governance structures and KPIs for each horizon.
This prevents H1's operational demands from stifling H2 and H3 innovation, allowing for different risk appetites, timelines, and success metrics appropriate for each horizon.
Develop a multi-year innovation roadmap clearly outlining H1, H2, and H3 initiatives with specific resource allocations and milestones.
A clear roadmap ensures transparency, aligns internal stakeholders, and facilitates strategic budgeting, enabling effective R&D portfolio prioritization and long-term planning.
Actively scout and engage in strategic partnerships, venture investments, or M&A tailored to H2 and H3 technologies.
External collaborations can accelerate development in new areas, bring in specialized expertise, and de-risk investments in emerging technologies, addressing talent gaps and high R&D burdens.
Implement a 'Regulatory Horizons' strategy, dedicating resources to anticipate and influence future regulatory landscapes for H3 technologies.
Proactive engagement with regulatory bodies (e.g., FDA, EMA) for breakthrough devices can significantly shorten time-to-market and shape favorable regulatory pathways for disruptive innovations.
From quick wins to long-term transformation
- Audit current R&D projects and product portfolio, categorizing each into H1, H2, or H3.
- Communicate the Three Horizons concept across the organization to foster a shared understanding of innovation priorities.
- Allocate a small, dedicated 'future fund' for H3 exploratory projects, even if small in scale.
- Establish distinct KPIs and reporting mechanisms for each horizon to track progress and success independently.
- Create a cross-functional 'Innovation Council' responsible for overseeing and integrating horizon strategies.
- Pilot dedicated internal incubators or innovation labs for H2 and H3 projects, distinct from core business operations.
- Integrate the Three Horizons framework into the annual strategic planning and budgeting process at the corporate level.
- Develop formal 'handoff' processes for transitioning successful H2 projects to H1, and H3 to H2.
- Cultivate a company-wide culture that values both incremental improvements and disruptive breakthroughs, with appropriate recognition systems.
- H1's 'tyranny of the present' consuming resources and attention meant for H2 and H3.
- Lack of clear transition mechanisms between horizons, leading to 'orphan' projects.
- Insufficient funding or commitment for H3, resulting in missed future opportunities.
- Organizational resistance to change or fear of cannibalizing H1 products.
- Inability to attract and retain specialized talent required for H2 and H3 innovations (IN02, ER07).
Measuring strategic progress
| Metric | Description | Target Benchmark |
|---|---|---|
| R&D Spend by Horizon (% of total R&D) | Percentage of total R&D budget allocated to H1 (incremental), H2 (transformational), and H3 (disruptive) projects. | Achieve 70:20:10 or 60:30:10 split for H1:H2:H3 by year 3. |
| Innovation Pipeline Value by Horizon | Estimated future revenue or market potential of projects within each horizon. | Increase H2 pipeline value by 25% year-over-year; establish viable H3 options. |
| Revenue Contribution by Horizon | Percentage of total company revenue generated by products launched from H1, H2, and H3 initiatives. | Target 15-20% of revenue from H2 products within 5 years; 5% from H3 within 10 years. |
| Time-to-Market (H2/H3 projects) | Average time taken from project inception to market launch for H2 and H3 products, specifically tracking regulatory approval phases. | Reduce average H2 time-to-market by 10% through streamlined processes. |
| Strategic Partnership Success Rate (H2/H3) | Number of H2/H3-focused partnerships that lead to successful product development or market entry. | Achieve a 60% success rate for H2/H3 strategic partnerships. |
Other strategy analyses for Manufacture of irradiation, electromedical and electrotherapeutic equipment
Also see: Three Horizons Framework Framework